Androgen deprivation therapy

Castration-resistant prostate cancer ( CRPC ) is defined as disease progression during ADT ( androgen deprivation therapy ), with serum...


The phase III SPARTAN study evaluated Apalutamide ( Erleada ) vs Placebo in patients with non-metastatic castration-resistant prostate cancer (...


Lynparza ( Olaparib ) has been approved in the European Union ( EU ) for patients with metastatic castration-resistant prostate...


The American Cancer Society estimates that in 2020, there will have been more than 190,000 cases of prostate cancer in...


The Food and Drug Administration ( FDA ) has approved the first oral gonadotropin-releasing hormone ( GnRH ) receptor antagonist,...


The European Commission ( EC ) has granted marketing authorisation for the expanded use of Erleada ( Apalutamide ) to...


SPARTAN has evaluated Apalutamide ( Erleada ) versus placebo in patients with nonmetastatic castration-resistant prostate cancer ( nmCRPC ) and...


Darolutamide ( Nubeqa ) is a structurally distinct androgen receptor inhibitor with a favorable safety profile, approved for treating men...


Tthe phase III IPATential150 study met its co-primary endpoint of radiographic progression-free survival ( rPFS ) in patients with metastatic...


The European Commission ( EC ) has granted marketing authorisation for Erleada ( Apalutamide ), a next generation oral androgen...


Results from the phase 3 TITAN study were presented in an oral session at the American Society of Clinical...


For patients with prostate cancer, treating the disease with androgen deprivation therapy ( ADT ) is linked to a...


Data, presented at 2018 American Society of Clinical Oncology ( ASCO ) Annual Meeting, showed clinical improvement in median radiologic...


Radium-223 dichloride ( Ra-233; Xofigo ), a bone targeting alpha radiopharmaceutical, and Enzalutamide ( Xtandi ), are approved for metastatic...


The PROSPER trial has shown a clinically and statistically significant improvement in metastasis-free survival ( hazard ratio, HR=0.292 [ 95%...


The results from the phase 3 PROSPER trial in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CRPC...


New findings were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium ( ASCO GU ) in San...


A new analysis of patients who have undergone treatment for prostate cancer shows a connection between androgen deprivation therapy (...


Data from the pivotal phase 3 LATITUDE clinical trial showed Abiraterone acetate ( Zytiga ) plus Prednisone, in combination with...


STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of...